Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

NeoGenomics, Inc. operates a network of clinical laboratories that specializes in cancer genetics diagnostic testing services. The Company"s services include cytogenetics, fluorescence in-situhybridization (FISH), flow cytometry, morphology, anatomic pathology, and molecular genetic testing. NeoGenomics serves pathologists, oncologists, urologists, and hospitals.
Website: neogenomics.com



Growth: Good revenue growth rate 11.9%, there is slowdown compared to average historical growth rates 12.6%. The revenue growth dynamics is stable Site traffic for the last 3 months showed a change of -16.3%

Profitability: LTM EBITDA margin is negative, -7.2%. On average the margin is decreasing steadily. Gross margin is high, +42.8%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.06 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -1.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 156.8% higher than minimum and 40.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.8x by EV / Sales multiple , the company can be 31.7% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.5 mln (-0.034% of cap.)

Key Financials (Download financials)

Ticker: NEO
Share price, USD:  (0.0%)12.43
year average price 9.35  


year start price 13.45 2025-02-08

max close price 14.42 2025-02-14

min close price 4.84 2025-07-31

current price 12.43 2026-02-07
Common stocks: 128 415 000

Dividend Yield:  0.0%
EV / Sales: 2.6x
Margin (EBITDA LTM / Revenue): -7.2%
Fundamental value created in LTM:
Market Cap ($m): 1 596
Net Debt ($m): 246
EV (Enterprise Value): 1 842
Price to Book: 1.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-27businesswire.com

NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

2026-01-25seekingalpha.com

NeoGenomics: Distribution Moat In Community Oncology

2026-01-22businesswire.com

Better Marks One-Year Partnership with NEO Home Loans — NEO Loan Officers See 91% Growth in Funded Loans 6 Months After Implementing Tinman® AI Platform

2026-01-14seekingalpha.com

NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-12businesswire.com

NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

2025-12-30businesswire.com

NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors

2025-12-15businesswire.com

NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

2025-12-10businesswire.com

NeoGenomics to Present New ctDNA Research at SABCS 2025

2025-12-09prnewswire.com

AerCap Signs Lease Agreements with New Customer My Freighter for Two New Airbus A321NEO Aircraft

2025-12-08businesswire.com

UK: TotalEnergies Merges Its Upstream Business with NEO NEXT, Creating the Largest Independent Oil and Gas Producer in the UK
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-28 2025-07-29 2024-11-05 2024-07-30 2024-04-30 2023-11-06 2023-08-08 2023-05-09 2022-11-08
acceptedDate 2025-10-28 16:05:09 2025-07-29 07:22:17 2025-02-18 16:16:39 2024-11-05 16:06:48 2024-07-30 16:04:53 2024-04-30 16:10:35 2024-02-20 16:23:05 2023-11-06 16:29:54 2023-08-08 16:49:53 2023-05-09 16:38:46 2023-02-24 16:39:33 2022-11-08 16:42:51 2022-02-25 16:50:25 2021-02-25 17:00:45
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 188M 181M 661M 168M 165M 156M 592M 152M 147M 137M 510M 129M 484M 444M
costOfRevenue 107M 104M 370M 93M 95M 94M 347M 90M 87M 82M 322M 80M 297M 259M
grossProfit 80M 77M 290M 75M 69M 62M 245M 62M 60M 55M 188M 49M 187M 186M
grossProfitRatio 0.428 0.426 0.446 0.42 0.397 0.41 0.408 0.399 0.38
researchAndDevelopmentExpenses 9M 9M 31M 8M 8M 8M 27M 5M 8M 7M 30M 7M 22M 8M
generalAndAdministrativeExpenses 70M 72M 226M 67M 63M 66M 209M 61M 60M 62M 211M 64M 221M 144M
sellingAndMarketingExpenses 22M 24M 85M 20M 22M 20M 71M 18M 19M 16M 67M 17M 63M 48M
sellingGeneralAndAdministrativeExpenses 92M 96M 310M 87M 82M 83M 280M 79M 79M 78M 278M 81M 284M 192M
otherExpenses 7M 20M 41M 0 -2000 -263 000 45M -96 000 730 000 -114 000 37M 0 0 0
operatingExpenses 107M 125M 382M 95M 89M 90M 352M 84M 87M 85M 346M 88M 306M 200M
costAndExpenses 215M 229M 753M 188M 185M 184M 699M 174M 174M 168M 667M 168M 603M 458M
interestIncome 2M 2M 18M 5M 5M 5M 17M 3M 0 0 6M 0 3M 0
interestExpense 0 933 000 7M 2M 2M 2M 7M -3M -3M -1M 8M 139 000 8M 7M
depreciationAndAmortization 16M 17M 73M 18M 18M 18M 73M 18M 18M 23M 69M 17M 53M 42M
ebitda -10M -28M -2M 2M 756 000 -10M -18M -2M -5M -8M -82M -22M -65M 35M
ebitdaratio -0.053 -0.152 0.011 -0.014 -0.063 -0.012 -0.037 -0.057 -0.171
operatingIncome -27M -48M -92M -21M -20M -28M -108M -24M -30M -30M -158M -40M -119M -14M
operatingIncomeRatio -0.144 -0.263 -0.126 -0.124 -0.18 -0.159 -0.203 -0.221 -0.307
totalOtherIncomeExpensesNet 625 000 2M 11M 3M 3M 488 000 11M -2M -2M -3M -2M -114 000 104M -64 000
incomeBeforeTax -26M -46M -81M -18M -19M -28M -97M -21M -27M -34M -159M -40M -15M -14M
incomeBeforeTaxRatio -0.141 -0.253 -0.106 -0.116 -0.177 -0.141 -0.181 -0.246 -0.308
incomeTaxExpense 740 000 -724 000 -2M -150 000 -375 000 -620 000 -9M -3M -2M -3M -15M -3M -7M -18M
netIncome -27M -45M -79M -18M -19M -27M -88M -19M -24M -31M -144M -37M -8M 4M
netIncomeRatio -0.144 -0.249 -0.105 -0.113 -0.173 -0.122 -0.166 -0.224 -0.286
eps -1.05 -1.75 -3.1 -0.14 -0.15 -0.21 -3.5 -0.15 -0.19 -0.25 -5.8 -0.3 -0.35 0.19
epsdiluted -1.05 -1.75 -0.14 -0.15 -0.21 -0.15 -0.19 -0.25 -0.3
weightedAverageShsOut 26M 26M 25M 127M 126M 126M 25M 126M 125M 125M 25M 124M 24M 22M
weightedAverageShsOutDil 26M 26M 25M 127M 126M 126M 25M 126M 125M 125M 25M 124M 24M 22M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-18 2024-02-20 2023-02-24 2022-02-25 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 12M 10M -2M -5M -7M
ebit -74M -90M -152M -119M -7M
nonOperatingIncomeExcludingInterest -18M -18M -6M 0 -7M
netIncomeFromContinuingOperations -79M -88M -144M -8M 4M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -79M -88M -144M -8M 4M
epsDiluted -3.1 -3.5 -5.8 -0.35 0.19

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-28 2025-07-29 2024-11-05 2024-07-30 2024-04-30 2023-11-06 2023-08-08 2023-05-09 2022-11-08
acceptedDate 2025-10-28 16:05:09 2025-07-29 07:22:17 2025-02-18 16:16:39 2024-11-05 16:06:48 2024-07-30 16:04:53 2024-04-30 16:10:35 2024-02-20 16:23:05 2023-11-06 16:29:54 2023-08-08 16:49:53 2023-05-09 16:38:46 2023-02-24 16:39:33 2022-11-08 16:42:51 2022-02-25 16:50:25 2021-02-25 17:00:45
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 164M 155M 367M 362M 355M 332M 342M 306M 289M 276M 263M 266M 317M 229M
shortTermInvestments 0 9M 20M 26M 33M 53M 73M 96M 120M 142M 175M 177M 199M 68M
cashAndShortTermInvestments 164M 164M 387M 388M 388M 385M 415M 402M 409M 418M 438M 444M 515M 296M
netReceivables 156M 154M 151M 151M 147M 142M 131M 133M 125M 119M 120M 112M 112M 107M
inventory 28M 34M 27M 24M 23M 20M 24M 24M 25M 24M 24M 24M 23M 30M
otherCurrentAssets 34M 41M 12M 27M 27M 27M 8M 9M 8M 8M 8M 8M 18M 5M
totalCurrentAssets 382M 392M 596M 590M 584M 574M 597M 587M 585M 585M 605M 603M 682M 449M
propertyPlantEquipmentNet 166M 168M 174M 174M 176M 174M 184M 182M 192M 197M 199M 206M 212M 152M
goodwill 524M 524M 523M 523M 523M 523M 523M 523M 523M 523M 523M 523M 527M 211M
intangibleAssets 294M 302M 340M 348M 356M 365M 373M 382M 391M 399M 408M 417M 442M 121M
goodwillAndIntangibleAssets 819M 826M 862M 871M 879M 888M 896M 905M 913M 922M 931M 940M 969M 332M
longTermInvestments 0 0 0 0 -23M -23M 0 -25M -29M 0 31 000 0 236 000 30M
taxAssets 0 0 0 0 23M 23M 0 25M 29M 32M 35M 0 55M 5M
otherNonCurrentAssets 8M 7M 6M 6M 4M 4M 5M 5M 5M -26M -30M 7M -49M 21M
totalNonCurrentAssets 992M 1 002M 1 042M 1 051M 1 059M 1 066M 1 084M 1 091M 1 110M 1 124M 1 135M 1 152M 1 188M 540M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 375M 1 394M 1 638M 1 641M 1 643M 1 640M 1 681M 1 678M 1 695M 1 709M 1 740M 1 756M 1 870M 988M
accountPayables 23M 27M 22M 17M 17M 18M 20M 17M 87M 80M 21M 14M 18M 25M
shortTermDebt 5M 4M 201M 204M 204M 4M 0 6M 7M 7M 0 6M 1M 3M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 2M 1M 409 000 589 000 972 000 1M 2M 4M 6M 6M 8M 6M 5M 4M
otherCurrentLiabilities 69M 67M 75M 75M 68M 53M 53M 66M -6M -6M 15M 58M 17M 0
totalCurrentLiabilities 98M 100M 301M 296M 290M 77M 96M 93M 95M 87M 90M 85M 87M 73M
longTermDebt 406M 408M 340M 402M 403M 539M 538M 599M 602M 603M 535M 605M 532M 168M
deferredRevenueNonCurrent 507 000 443 000 0 396 000 349 000 65M 0 0 0 0 19 000 0 917 000 712 000
deferredTaxLiabilitiesNonCurrent 21M 20M 22M 23M 23M 23M 24M 25M 29M 32M 35M 38M 55M 5M
otherNonCurrentLiabilities 11M 12M 12M 11M 12M 13M 13M 13M 13M 13M 13M 631M 13M 3M
totalNonCurrentLiabilities 439M 440M 434M 436M 437M 640M 643M 638M 644M 648M 652M 658M 674M 221M
otherLiabilities 0 0 0 1 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 64M 67M 64M 66M 67M 65M 73M 68M 73M 74M 76M 77M 80M 48M
totalLiabilities 536M 540M 736M 733M 727M 717M 740M 731M 739M 735M 742M 743M 762M 294M
preferredStock 0 0 0 0 294M 0 0 0 0 0 0 0 0 0
commonStock 128 000 128 000 128 000 128 000 128 000 127 000 127 000 127 000 127 000 127 000 127 000 127 000 124 000 112 000
retainedEarnings -424M -397M -326M -310M -293M -274M -247M -233M -214M -190M -159M -136M -15M -7M
accumulatedOtherComprehensiveIncomeLoss 71 000 29 000 -206 000 -643 000 -1M -1M -2M -2M -3M -3M -4M -5M -638 000 10000
othertotalStockholdersEquity 1 262M 1 251M 1 219M 1 210M 1 199M 1 182M 1 173M 1 167M 1 154M
totalStockholdersEquity 838M 854M 902M 908M 916M 923M 942M 947M 956M 974M 998M 1 013M 1 108M 694M
totalEquity 838M 854M 902M 908M 916M 923M 942M 947M 956M 974M 998M 1 013M 1 108M 694M
totalLiabilitiesAndStockholdersEquity 1 375M 1 394M 1 641M 1 643M 1 640M 1 678M 1 695M 1 709M 1 756M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 375M 1 394M 1 638M 1 641M 1 643M 1 640M 1 681M 1 678M 1 695M 1 709M 1 740M 1 756M 1 870M 988M
totalInvestments 0 9M 20M 26M 33M 53M 73M 96M 120M 142M 175M 177M 199M 97M
totalDebt 410M 412M 605M 606M 607M 608M 612M 606M 610M 610M 611M 612M 613M 218M
netDebt 246M 257M 238M 244M 251M 276M 269M 299M 321M 335M 348M 345M 296M -10M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-18 2024-02-20 2023-02-24 2022-02-25 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 151M 131M 120M 112M 107M
otherReceivables 0 0 0 0 0
prepaids 20M 18M 15M 12M 12M
totalPayables 22M 20M 21M 18M 25M
otherPayables 0 0 0 0 0
accruedExpenses 0 15M 40M 38M 36M
capitalLeaseObligationsCurrent 3M 6M 7M 8M 5M
capitalLeaseObligationsNonCurrent 61M 68M 69M 72M 43M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 228M 1 190M 1 161M 1 124M 701M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO NEO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-28 2025-07-29 2024-11-05 2024-07-30 2024-04-30 2023-11-06 2023-08-08 2023-05-09 2022-11-08
acceptedDate 2025-10-28 16:05:09 2025-07-29 07:22:17 2025-02-18 16:16:39 2024-11-05 16:06:48 2024-07-30 16:04:53 2024-04-30 16:10:35 2024-02-20 16:23:05 2023-11-06 16:29:54 2023-08-08 16:49:53 2023-05-09 16:38:46 2023-02-24 16:39:33 2022-11-08 16:42:51 2022-02-25 16:50:25 2021-02-25 17:00:45
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -27M -45M -79M -18M -19M -27M -88M -19M -24M -31M -144M -37M -8M 4M
depreciationAndAmortization 16M 17M 73M 18M 18M 18M 73M 18M 18M 18M 69M 17M 53M 36M
deferredIncomeTax 0 0 0 795 000 0 -795 000 0 2M -923 000 -3M -16M 0 0 951 000
stockBasedCompensation 10M 12M 33M 8M 9M 8M 25M 7M 6M 5M 25M 4M 22M 10M
changeInWorkingCapital -226 000 14M -33M -3M 2M -28M -25M -16M -5M -8M -32M -7M -5M -62M
accountsReceivables -2M 1M -19M -5M -6M -9M -12M -7M -7M 870 000 -8M -718 000 -5M -13M
inventory 6M -4M -3M -1M -3M 4M -454 000 636 000 -688 000 -200 000 -1M -2M 2M -15M
accountsPayables -6M 7M -4M 5M -5M -138 000 -5M -2M -5M 4M 3M -3M 19M -4M
otherWorkingCapital 2M 10M -7M -1M 16M -23M -9M -7M 7M -13M -26M -1M -21M -30M
otherNonCashItems 9M 22M 12M 2M 63M 53M 14M 1M 5M 7M 32M 6M -90M 12M
netCashProvidedByOperatingActivities 9M 20M 7M 9M 14M -26M -2M -5M -2M -13M -66M -16M -27M 1M
investmentsInPropertyPlantAndEquipment -8M -6M -41M -11M -13M -6M -29M -4M -7M -10M -31M -8M -64M -29M
acquisitionsNet -463 000 -6M 0 0 0 0 0 0 0 0 0 0 -419M -37M
purchasesOfInvestments 0 0 0 0 0 0 -7M 0 0 -7M -98M -18M -197M -99M
salesMaturitiesOfInvestments 9M 3M 54M 7M 20M 20M 112M 25M 22M 40M 117M 21M 63M 5M
otherInvestingActivites -500 000 0 0 20M 20M 25M 0 0 0
netCashUsedForInvestingActivites -277 000 -9M -4M 7M 15M 21M 15M 24M -4M
debtRepayment 0 -201M 0 0 0 -5000 0 -32 000 -132 000
commonStockIssued 765 000 -1M 1M 2M 816 000 2M 93 000 1M 3M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 0 0 816 000 -5000 -29 000 0 0
netCashUsedProvidedByFinancingActivities 765 000 -202M 1M 2M 816 000 2M 64 000 1M 3M
effectOfForexChangesOnCash 0 -54 000 0 0 0 0 0 -36M 0 0 0 0 0 0
netChangeInCash 9M -191M 25M 7M 23M -11M 79M 17M 13M 12M -54M -18M 66M 78M
cashAtEndOfPeriod 164M 155M 367M 362M 355M 332M 342M 306M 289M 276M 263M 266M 317M 251M
cashAtBeginningOfPeriod 155M 346M 342M 355M 332M 342M 263M 289M 276M 263M 317M 284M 251M 173M
operatingCashFlow 9M 20M 7M 9M 14M -26M -2M -5M -2M -13M -66M -16M -27M 1M
capitalExpenditure -8M -6M -41M -11M -13M -6M -29M -4M -7M -10M -31M -8M -64M -29M
freeCashFlow 570 000 14M -34M -2M 814 000 -32M -31M -10M -9M -23M -97M -24M -91M -28M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-18 2024-02-20 2023-02-24 2022-02-25 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 12M -15M 0
netCashProvidedByInvestingActivities 13M 77M 517 000 -632M -159M
netDebtIssuance 0 -70 000 -758 000 334M 91M
longTermNetDebtIssuance 0 -70 000 -758 000 334M 97M
shortTermNetDebtIssuance 0 0 0 0 -6M
netStockIssuance 5M 5M 13M 423M 148M
netCommonStockIssuance 5M 5M 13M 423M 148M
commonStockIssuance 5M 5M 13M 423M 148M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 -32M -3M
netCashProvidedByFinancingActivities 5M 5M 12M 725M 236M
incomeTaxesPaid 207 000 175 000 180 000 148 000 246 000
interestPaid 4M 3M 3M 3M 3M

Earning call transcript

2025 q3
2025-10-28 ET (fiscal 2025 q3)
2025 q2
2025-07-29 ET (fiscal 2025 q2)
2025 q1
2025-04-29 ET (fiscal 2025 q1)
2024 q4
2025-02-18 ET (fiscal 2024 q4)
2024 q3
2024-11-05 ET (fiscal 2024 q3)
2024 q2
2024-07-29 ET (fiscal 2024 q2)
2024 q1
2024-04-30 ET (fiscal 2024 q1)
2023 q4
2024-02-20 ET (fiscal 2023 q4)
2023 q3
2023-11-06 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-08 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-04-27 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-10-28 20:05 ET
NeoGenomics reported for 2025 q3
SEC form 8
2025-10-28 11:09 ET
NeoGenomics published news for 2025 q3
SEC form 8
2025-10-28 11:09 ET
NeoGenomics reported for 2025 q3
SEC form 10
2025-07-29 11:22 ET
NeoGenomics reported for 2025 q2
SEC form 8
2025-07-29 11:08 ET
NeoGenomics published news for 2025 q2
SEC form 8
2025-07-29 11:08 ET
NeoGenomics reported for 2025 q2
SEC form 10
2025-04-29 00:00 ET
NeoGenomics reported for 2025 q1
SEC form 8
2025-04-29 00:00 ET
NeoGenomics published news for 2025 q1
SEC form 8
2025-04-29 00:00 ET
NeoGenomics reported for 2025 q1
SEC form 10
2025-02-18 00:00 ET
NeoGenomics reported for 2024 q4
SEC form 8
2025-02-18 00:00 ET
NeoGenomics published news for 2024 q4
SEC form 8
2025-02-18 00:00 ET
NeoGenomics published news for 2024 q4
SEC form 10
2024-11-05 16:06 ET
NeoGenomics published news for 2024 q3
SEC form 8
2024-11-05 07:14 ET
NeoGenomics published news for 2024 q3
SEC form 8
2024-11-05 07:14 ET
NeoGenomics published news for 2024 q3
SEC form 10
2024-07-30 16:04 ET
NeoGenomics published news for 2024 q2
SEC form 10
2024-07-30 00:00 ET
NeoGenomics published news for 2024 q2
SEC form 8
2024-07-29 16:08 ET
NeoGenomics published news for 2024 q2
SEC form 8
2024-07-29 16:08 ET
NeoGenomics reported for 2024 q2
SEC form 10
2024-04-30 16:10 ET
NeoGenomics published news for 2024 q1
SEC form 8
2024-04-30 07:32 ET
NeoGenomics published news for 2024 q1
SEC form 8
2024-04-30 07:32 ET
NeoGenomics reported for 2024 q1
SEC form 10
2024-04-30 00:00 ET
NeoGenomics published news for 2024 q1
SEC form 10
2024-02-20 16:23 ET
NeoGenomics published news for 2023 q4
SEC form 8
2024-02-20 16:06 ET
NeoGenomics published news for 2023 q4
SEC form 8
2024-02-20 16:06 ET
NeoGenomics reported for 2023 q4
SEC form 10
2024-02-20 00:00 ET
NeoGenomics published news for 2023 q4
SEC form 10
2023-11-06 16:29 ET
NeoGenomics published news for 2023 q3
SEC form 8
2023-11-06 16:18 ET
NeoGenomics reported for 2023 q3
SEC form 10
2023-11-06 00:00 ET
NeoGenomics published news for 2023 q3
SEC form 10
2023-08-08 16:49 ET
NeoGenomics published news for 2023 q2
SEC form 6
2023-08-08 07:03 ET
NeoGenomics reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
NeoGenomics published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
NeoGenomics published news for 2023 q2
SEC form 6
2023-07-07 18:02 ET
NeoGenomics published news for 2023 q2
SEC form 6
2023-07-06 19:15 ET
NeoGenomics published news for 2023 q2
SEC form 6
2023-07-06 18:31 ET
NeoGenomics published news for 2023 q2
SEC form 6
2023-06-29 16:21 ET
NeoGenomics published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
NeoGenomics published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
NeoGenomics reported for 2023 q1
SEC form 6
2023-04-04 14:54 ET
NeoGenomics published news for 2023 q1
SEC form 10
2023-02-24 16:39 ET
NeoGenomics reported for 2022 q4
SEC form 10
2023-02-24 00:00 ET
NeoGenomics reported for 2022 q4
SEC form 6
2023-02-23 07:13 ET
NeoGenomics published news for 2022 q4
SEC form 8
2023-02-23 00:00 ET
NeoGenomics reported for 2022 q4
SEC form 6
2023-01-23 16:30 ET
NeoGenomics published news for 2022 q4
SEC form 6
2022-12-15 20:02 ET
NeoGenomics published news for 2022 q3
SEC form 6
2022-12-07 20:46 ET
NeoGenomics published news for 2022 q3
SEC form 6
2022-12-05 21:40 ET
NeoGenomics published news for 2022 q3
SEC form 6
2022-12-01 18:07 ET
NeoGenomics published news for 2022 q3
SEC form 6
2022-11-18 16:29 ET
NeoGenomics published news for 2022 q3
SEC form 10
2022-11-08 16:42 ET
NeoGenomics reported for 2022 q3
SEC form 6
2022-11-08 07:07 ET
NeoGenomics published news for 2022 q3
SEC form 10
2022-11-08 00:00 ET
NeoGenomics reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
NeoGenomics reported for 2022 q3
SEC form 6
2022-11-07 17:11 ET
NeoGenomics published news for 2022 q3
SEC form 6
2022-11-07 16:54 ET
NeoGenomics published news for 2022 q3
SEC form 6
2022-10-20 16:50 ET
NeoGenomics published news for 2022 q3
SEC form 6
2022-08-17 19:11 ET
NeoGenomics published news for 2022 q2
SEC form 6
2022-08-12 16:34 ET
NeoGenomics published news for 2022 q2
SEC form 10
2022-08-09 16:41 ET
NeoGenomics reported for 2022 q2
SEC form 6
2022-08-09 07:05 ET
NeoGenomics published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
NeoGenomics reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
NeoGenomics reported for 2022 q2
SEC form 6
2022-07-21 16:41 ET
NeoGenomics published news for 2022 q2
SEC form 6
2022-07-18 16:31 ET
NeoGenomics published news for 2022 q2
SEC form 6
2022-07-15 17:33 ET
NeoGenomics published news for 2022 q2
SEC form 6
2022-06-14 20:43 ET
NeoGenomics published news for 2022 q1
SEC form 6
2022-06-14 20:43 ET
NeoGenomics published news for 2022 q1
SEC form 6
2022-06-14 20:42 ET
NeoGenomics published news for 2022 q1
SEC form 6
2022-06-14 20:42 ET
NeoGenomics published news for 2022 q1
SEC form 6
2022-06-14 20:42 ET
NeoGenomics published news for 2022 q1
SEC form 6
2022-06-14 20:41 ET
NeoGenomics published news for 2022 q1
SEC form 6
2022-06-03 16:16 ET
NeoGenomics published news for 2022 q1
SEC form 6
2022-06-02 18:28 ET
NeoGenomics published news for 2022 q1
SEC form 6
2022-05-20 17:08 ET
NeoGenomics published news for 2022 q1
SEC form 6
2022-05-16 10:13 ET
NeoGenomics published news for 2022 q1
SEC form 6
2022-05-11 17:02 ET
NeoGenomics published news for 2022 q1
SEC form 10
2022-05-09 16:21 ET
NeoGenomics reported for 2022 q1
SEC form 10
2022-05-09 00:00 ET
NeoGenomics reported for 2022 q1
SEC form 6
2022-05-06 16:34 ET
NeoGenomics published news for 2022 q1
SEC form 6
2022-04-27 07:19 ET
NeoGenomics published news for 2022 q1
SEC form 8
2022-04-27 00:00 ET
NeoGenomics reported for 2022 q1
SEC form 6
2022-04-25 16:30 ET
NeoGenomics published news for 2022 q1
SEC form 6
2022-04-14 16:23 ET
NeoGenomics published news for 2022 q1
SEC form 6
2022-04-14 16:09 ET
NeoGenomics published news for 2022 q1
SEC form 6
2022-03-28 16:20 ET
NeoGenomics published news for 2021 q4
SEC form 6
2022-03-21 16:25 ET
NeoGenomics published news for 2021 q4
SEC form 6
2022-03-09 08:57 ET
NeoGenomics published news for 2021 q4
SEC form 6
2022-03-03 19:59 ET
NeoGenomics published news for 2021 q4
SEC form 6
2022-03-03 19:58 ET
NeoGenomics published news for 2021 q4
SEC form 6
2022-03-03 19:58 ET
NeoGenomics published news for 2021 q4
SEC form 6
2022-03-03 19:57 ET
NeoGenomics published news for 2021 q4
SEC form 6
2022-03-03 19:57 ET
NeoGenomics published news for 2021 q4
SEC form 6
2022-03-03 19:56 ET
NeoGenomics published news for 2021 q4
SEC form 10
2022-02-25 16:50 ET
NeoGenomics published news for 2021 q4
SEC form 10
2022-02-25 00:00 ET
NeoGenomics published news for 2021 q4
SEC form 6
2022-02-23 07:14 ET
NeoGenomics published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
NeoGenomics published news for 2021 q4
SEC form 6
2022-01-19 16:27 ET
NeoGenomics published news for 2021 q4
SEC form 6
2021-11-10 17:06 ET
NeoGenomics published news for 2021 q3
SEC form 10
2021-11-04 17:00 ET
NeoGenomics published news for 2021 q3
SEC form 6
2021-11-04 07:23 ET
NeoGenomics published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
NeoGenomics published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
NeoGenomics published news for 2021 q3
SEC form 6
2021-10-12 17:03 ET
NeoGenomics published news for 2021 q3
SEC form 6
2021-09-01 16:34 ET
NeoGenomics published news for 2021 q2
SEC form 6
2021-08-10 17:09 ET
NeoGenomics published news for 2021 q2
SEC form 10
2021-08-09 16:08 ET
NeoGenomics published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
NeoGenomics published news for 2021 q2
SEC form 6
2021-08-06 07:10 ET
NeoGenomics published news for 2021 q2
SEC form 8
2021-08-06 00:00 ET
NeoGenomics published news for 2021 q2
SEC form 6
2021-07-15 16:39 ET
NeoGenomics published news for 2021 q2
SEC form 6
2021-07-07 17:21 ET
NeoGenomics published news for 2021 q2
SEC form 6
2021-06-24 16:45 ET
NeoGenomics published news for 2021 q1
SEC form 6
2021-06-08 17:07 ET
NeoGenomics published news for 2021 q1
SEC form 6
2021-06-01 16:16 ET
NeoGenomics published news for 2021 q1
SEC form 6
2021-05-06 17:07 ET
NeoGenomics published news for 2021 q1
SEC form 10
2021-05-06 17:01 ET
NeoGenomics published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
NeoGenomics published news for 2021 q1
SEC form 6
2021-05-05 07:36 ET
NeoGenomics published news for 2021 q1
SEC form 6
2021-05-05 07:32 ET
NeoGenomics published news for 2021 q1
SEC form 6
2021-05-05 07:31 ET
NeoGenomics published news for 2021 q1
SEC form 6
2021-05-05 07:30 ET
NeoGenomics published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
NeoGenomics published news for 2021 q1
SEC form 6
2021-04-26 17:48 ET
NeoGenomics published news for 2021 q1
SEC form 6
2021-04-15 16:42 ET
NeoGenomics published news for 2021 q1
SEC form 6
2021-04-15 16:40 ET
NeoGenomics published news for 2021 q1
SEC form 6
2021-04-15 16:32 ET
NeoGenomics published news for 2021 q1
SEC form 6
2021-04-07 17:23 ET
NeoGenomics published news for 2021 q1
SEC form 6
2021-03-24 16:45 ET
NeoGenomics published news for 2020 q4
SEC form 6
2021-03-01 16:45 ET
NeoGenomics published news for 2020 q4
SEC form 6
2021-02-25 17:08 ET
NeoGenomics published news for 2020 q4
SEC form 10
2021-02-25 17:00 ET
NeoGenomics published news for 2020 q4
SEC form 6
2021-02-24 07:51 ET
NeoGenomics published news for 2020 q4
SEC form 6
2021-01-11 17:16 ET
NeoGenomics published news for 2020 q4
SEC form 6
2021-01-11 17:13 ET
NeoGenomics published news for 2020 q4
SEC form 6
2021-01-05 16:01 ET
NeoGenomics published news for 2020 q4
SEC form 6
2020-12-15 20:51 ET
NeoGenomics published news for 2020 q3
SEC form 6
2020-10-29 17:19 ET
NeoGenomics published news for 2020 q3
SEC form 10
2020-10-29 17:17 ET
NeoGenomics published news for 2020 q3
SEC form 6
2020-10-27 07:59 ET
NeoGenomics published news for 2020 q3